Cefadroxil


Proficient Rx Lp
Human Prescription Drug
NDC 63187-883
Cefadroxil is a human prescription drug labeled by 'Proficient Rx Lp'. National Drug Code (NDC) number for Cefadroxil is 63187-883. This drug is available in dosage form of Capsule. The names of the active, medicinal ingredients in Cefadroxil drug includes Cefadroxil - 500 mg/1 . The currest status of Cefadroxil drug is Active.

Drug Information:

Drug NDC: 63187-883
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Cefadroxil
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Cefadroxil
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Proficient Rx Lp
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CEFADROXIL - 500 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 23 Apr, 2008
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA065392
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Proficient Rx LP
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:309049
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UPC:0363187883201
UPC stands for Universal Product Code.
UNII:280111G160
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Cephalosporin Antibacterial [EPC]
Cephalosporins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63187-883-066 CAPSULE in 1 BOTTLE (63187-883-06)02 Oct, 2017N/ANo
63187-883-2020 CAPSULE in 1 BOTTLE (63187-883-20)02 Oct, 2017N/ANo
63187-883-3030 CAPSULE in 1 BOTTLE (63187-883-30)02 Oct, 2017N/ANo
63187-883-4040 CAPSULE in 1 BOTTLE (63187-883-40)02 Oct, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Cefadroxil cefadroxil cefadroxil cefadroxil anhydrous d&c red no. 28 fd&c blue no. 1 fd&c red no. 40 gelatin, unspecified microcrystalline cellulose crospovidone (120 .mu.m) shellac potassium hydroxide magnesium stearate propylene glycol titanium dioxide ferrosoferric oxide maroon cap white body lu;f11

Indications and Usage:

Indications and usage cefadroxil capsules usp are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli , p. mirabilis , and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the developm
ent of drug-resistant bacteria and maintain the effectiveness of cefadroxil capsules and other antibacterial drugs, cefadroxil capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Warnings:

Warnings before therapy with cefadroxil monohydrate is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefadroxil, cephalosporins, penicillins, or other drugs. if this product is to be given to penicillin-sensitive patients, caution should be exercised because cross-sensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. if an allergic reaction to cefadroxil monohydrate occurs, discontinue the drug. serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated. clostridium difficile associated diarrhea (cdad) has been reported with use of nearly all antibacterial agents, including cefadroxil monohydrate, and may range in severity fr
om mild diarrhea to fatal colitis. treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of c. difficile . c. difficile produces toxins a and b which contribute to the development of cdad. hypertoxin producing strains of c. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. cdad must be considered in all patients who present with diarrhea following antibiotic use. careful medical history is necessary since cdad has been reported to occur over two months after the administration of antibacterial agents. if cdad is suspected or confirmed, ongoing antibiotic use not directed against c. difficile may need to be discontinued. appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of c. difficile , and surgical evaluation should be instituted as clinically indicated.

Dosage and Administration:

Dosage and administration cefadroxil capsules are acid-stable and may be administered orally without regard to meals. administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy. adults urinary tract infections : for uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.). for all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.). skin and skin structure infections : for skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.). pharyngitis and tonsillitis : treatment of group a beta-hemolytic streptococcal pharyngitis and tonsillitis— 1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days. children for urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses eve
ry 12 hours. for pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. for other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. in the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of cefadroxil monohydrate should be administered for at least 10 days. renal impairment in patients with renal impairment, the dosage of cefadroxil monohydrate should be adjusted according to creatinine clearance rates to prevent drug accumulation. the following schedule is suggested. in adults, the initial dose is 1000 mg of cefadroxil monohydrate and the maintenance dose (based on the creatinine clearance rate [ml/min/1.73 m ]) is 500 mg at the time intervals listed below. creatinine clearance dosage interval 0-10 ml/min 36 hours 10-25 ml/min 24 hours 25-50 ml/min 12 hours patients with creatinine clearance rates over 50 ml/min may be treated as if they were patients having normal renal function.

Contraindications:

Contraindications cefadroxil monohydrate is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Adverse Reactions:

Adverse reactions gastrointestinal onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see warnings ). dyspepsia, nausea and vomiting have been reported rarely. diarrhea has also occurred. hypersensitivity allergies (in the form of rash, urticaria, angioedema, and pruritus) have been observed. these reactions usually subsided upon discontinuation of the drug. anaphylaxis has also been reported. other other reactions have included hepatic dysfunction including cholestasis and elevations in serum transaminase, genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, stevens-johnson syndrome, serum sickness, and arthralgia have been rarely reported. in addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been repor
ted for cephalosporin-class antibiotics: toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive coombs' test, increased bun, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (ast), elevated alanine aminotransferase (alt), elevated bilirubin, elevated ldh, eosinophilia, pancytopenia, neutropenia. several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see dosage and administration and overdosage ). if seizures associated with drug therapy occur, the drug should be discontinued. anticonvulsant therapy can be given if clinically indicated.

Pediatric Use:

Pediatric use (see dosage and administration .)

Geriatric Use:

Geriatric use of approximately 650 patients who received cefadroxil for the treatment of urinary tract infections in three clinical trials, 28% were 60 years and older, while 16% were 70 years and older. of approximately 1000 patients who received cefadroxil for the treatment of skin and skin structure infection in 14 clinical trials, 12% were 60 years and older while 4% were 70 years and over. no overall differences in safety were observed between the elderly patients in these studies and younger patients. clinical studies of cefadroxil for the treatment of pharyngitis or tonsillitis did not include sufficient numbers of patients 65 years and older to determine whether they respond differently from younger patients. other reported clinical experience with cefadroxil has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. cefadroxil is substantially excreted by the kidney, and dosage adjustment is indicated for patients with renal impairment (see dosage and administration: renal impairment ). because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage a study of children under six years of age suggested that ingestion of less than 250 mg/ kg of cephalosporins is not associated with significant outcomes. no action is required other than general support and observation. for amounts greater than 250 mg/kg, induce gastric emptying. in five anuric patients, it was demonstrated that an average of 63% of a 1 g oral dose is extracted from the body during a 6–8 hour hemodialysis session.

Description:

Description cefadroxil monohydrate is a semisynthetic cephalosporin antibiotic intended for oral administration. it is a white to yellowish-white crystalline powder. it is soluble in water and it is acid-stable. it is chemically designated as 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate, [6r-[6α,7β(r*)]]-. it has the formula c 16 h 17 n 3 o 5 s•h 2 o and the molecular weight of 381.40. it has the following structural formula: each capsule contains cefadroxil monohydrate usp equivalent to 500 mg of cefadroxil. in addition, each capsule also contains the following inactive ingredients: crospovidone, d&c red no. 28, fd&c blue no. 1, fd&c red no. 40, ferric oxide black, gelatin, magnesium stearate, microcrystalline cellulose, potassium hydroxide, propylene glycol, shellac and titanium dioxide. molecular structure

Clinical Pharmacology:

Clinical pharmacology cefadroxil monohydrate is rapidly absorbed after oral administration. following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcg/ml, respectively. measurable levels were present 12 hours after administration. over 90% of the drug is excreted unchanged in the urine within 24 hours. peak urine concentrations are approximately 1800 mcg/ml during the period following a single 500-mg oral dose. increases in dosage generally produce a proportionate increase in cefadroxil monohydrate urinary concentration. the urine antibiotic concentration, following a 1-g dose, was maintained well above the mic of susceptible urinary pathogens for 20 to 22 hours. microbiology in vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. cefadroxil has been shown to be active against the following organisms both in vitro and in clinical infections (see indications and usage ):
beta-hemolytic streptococci staphylococci , including penicillinase-producing strains streptococcus (diplococcus) pneumoniae escherichia coli proteus mirabilis klebsiella species moraxella (branhamella) catarrhalis note: most strains of enterococcus faecalis (formerly streptococcus faecalis ) and enterococcus faecium (formerly streptococcus faecium ) are resistant to cefadroxil monohydrate. it is not active against most strains of enterobacter species, morganella morganii (formerly proteus morganii ), and p. vulgaris . it has no activity against pseudomonas species and acinetobacter calcoaceticus (formerly mima and herellea species). susceptibility tests: diffusion techniques the use of antibiotic disk susceptibility test methods which measure zone diameter give an accurate estimation of antibiotic susceptibility. one such standard procedure 1 which has been recommended for use with disks to test susceptibility of organisms to cefadroxil uses the cephalosporin class (cephalothin) disk. interpretation involves the correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (mic) for cefadroxil. reports from the laboratory giving results of the standard single-disk susceptibility test with a 30 mcg cephalothin disk should be interpreted according to the following criteria: zone diameter (mm) interpretation ≥ 18 (s) susceptible 15-17 (i) intermediate ≤ 14 (r) resistant a report of "susceptible" indicates that the pathogen is likely to be inhibited by generally achievable blood levels. a report of "intermediate susceptible" suggests that the organism would be susceptible if high dosage is used or if the infection is confined to tissue and fluids (e.g., urine) in which high antibiotic levels are attained. a report of "resistant'' indicates that achievable concentrations of the antibiotic are unlikely to be inhibitory and other therapy should be selected. standardized procedures require the use of laboratory control organisms. the 30 mcg cephalothin disk should give the following zone diameters: organism zone diameter (mm) staphylococcus aureus atcc 25923 29–37 escherichia coli atcc 25922 17–22 dilution techniques when using the nccls agar dilution or broth dilution (including microdilution) method or equivalent, a bacterial isolate may be considered susceptible if the mic (minimum inhibitory concentration) value for cephalothin is 8 mcg/ml or less. organisms are considered resistant if the mic is 32 mcg/ml or greater. organisms with an mic value of less than 32 mcg/ml but greater than 8 mcg/ml are intermediate. as with standard diffusion methods, dilution procedures require the use of laboratory control organisms. standard cephalothin powder should give mic values in the range of 0.12 mcg/ml and 0.5 mcg/ml for staphylococcus aureus atcc 29213. for escherichia coli atcc 25922, the mic range should be between 4 mcg/ml and 16 mcg/ml. for streptococcus faecalis atcc 29212, the mic range should be between 8 and 32 mcg/ml.

How Supplied:

How supplied cefadroxil capsules usp, 500 mg are size '0' capsules with maroon cap and white body, imprinted with "lu" (in black edible ink) on cap and with "f11" (in black edible ink) on body, containing white to off-white powder supplied as follows: ndc 63187-883-06 bottle of 06 store at 25°c (77°f); excursions permitted to 15° to 30° c (59° to 86° f). [see usp controlled room temperature].

Information for Patients:

Information for patients patients should be counseled that antibacterial drugs including cefadroxil capsules should only be used to treat bacterial infections. they do not treat viral infections (e.g., the common cold). when cefadroxil capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefadroxil capsules or other antibacterial drugs in the future. diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or m
ore months after having taken the last dose of the antibiotic. if this occurs, patients should contact their physician as soon as possible.

Package Label Principal Display Panel:

Package label.principal display panel cefadroxil capsules usp, 500 mg rx only package label – bottle of 20s ndc 63187-883-20 63187-883-20


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.